Antibody cocktail means happy days for treating mild Covid
AstraZeneca drug halves the risk of developing severe illness or death, tests reveal
AstraZeneca’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study that bolsters the drugmaker’s ambitions for the product.
The cocktail halved the risk of developing severe illness or death compared with a placebo in 822 participants who had been symptomatic for a week or less and weren’t hospitalised, Astra said in a statement on Monday.
The results are another boon for the injected product after it was also found to be highly effective at preventing symptomatic disease in high-risk people. The news comes after Merck & Co fuelled optimism that it will soon have the first Covid pill. Both treatments could offer a simple way to treat patients before they ever reach the hospital...